BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 16739232)

  • 1. Cross-trimester marker ratios in prenatal screening for Down syndrome.
    Wald NJ; Bestwick JP; Morris JK
    Prenat Diagn; 2006 Jun; 26(6):514-23. PubMed ID: 16739232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy.
    Wald NJ; Barnes IM; Birger R; Huttly W
    Prenat Diagn; 2006 Jun; 26(6):539-44. PubMed ID: 16634123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential and contingent prenatal screening for Down syndrome.
    Wald NJ; Rudnicka AR; Bestwick JP
    Prenat Diagn; 2006 Sep; 26(9):769-77. PubMed ID: 16821246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ; Densem JW; George L; Muttukrishna S; Knight PG
    Prenat Diagn; 1996 Feb; 16(2):143-53. PubMed ID: 8650125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.
    Wald NJ; Morris JK; Ibison J; Wu T; George LM
    Prenat Diagn; 2006 Jun; 26(6):559-64. PubMed ID: 16700087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
    Palomaki GE; Wright DE; Summers AM; Neveux LM; Meier C; O'donnell A; Huang T; Knight GJ; Haddow JE
    Prenat Diagn; 2006 Aug; 26(8):730-9. PubMed ID: 16810709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies.
    Cole LA; Acuna E; Isozaki T; Palomaki GE; Bahado-Singh RO; Mahoney MO
    Prenat Diagn; 1997 Dec; 17(12):1125-33. PubMed ID: 9467809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance.
    Rudnicka AR; Wald NJ; Huttly W; Hackshaw AK
    Prenat Diagn; 2002 Oct; 22(10):893-7. PubMed ID: 12378572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncation limits for CT marker ratios in prenatal screening for Down syndrome.
    Wald NJ; Bestwick JP; Morris JK
    Prenat Diagn; 2007 Feb; 27(2):187-8. PubMed ID: 17266161
    [No Abstract]   [Full Text] [Related]  

  • 12. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated measures screening for Down's Syndrome.
    Wright DE; Bradbury I
    BJOG; 2005 Jan; 112(1):80-3. PubMed ID: 15663402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated serum screening for Down syndrome in primary obstetric practice.
    Knight GJ; Palomaki GE; Neveux LM; Smith DE; Kloza EM; Pulkkinen AJ; Williams J; Haddow JE
    Prenat Diagn; 2005 Dec; 25(12):1162-7. PubMed ID: 16231402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening.
    Wright D; Bradbury I; Benn P; Cuckle H; Ritchie K
    Prenat Diagn; 2004 Oct; 24(10):762-6. PubMed ID: 15503281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-stage contingent screening for Down syndrome.
    Wright D; Bradbury I; Cuckle H; Gardosi J; Tonks A; Standing S; Benn P
    Prenat Diagn; 2006 Jun; 26(6):528-34. PubMed ID: 16634118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
    Talbot JA; Spencer K; Abushoufa RA
    Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.